前立腺がん(Prostate Cancer):治療薬開発のグローバルパイプライン動向(2014年下半期版)

調査会社Global Markets Direct社が発行したリサーチレポート(データ管理コード:GMDHC5311IDB)
◆英語タイトル:Prostate Cancer - Pipeline Review, H2 2014
◆発行会社/調査会社:Global Markets Direct
◆商品コード:GMDHC5311IDB
◆発行日:2014年8月31日
◆調査対象地域:グローバル
◆産業分野:製薬
◆ページ数:1366
◆レポート言語:英語
◆レポート形式:PDF
◆納品方式:Eメール
◆販売価格オプション(消費税別)
Single UserUSD2,500 ⇒換算¥275,000見積依頼/購入/質問フォーム
Site License(同一国内共有可)USD5,000 ⇒換算¥550,000見積依頼/購入/質問フォーム
Global Site License(複数国内共有可)USD7,500 ⇒換算¥825,000見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらで、ご購入に関する詳細案内はご利用ガイドでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日~2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。(振込先:三菱UFJ銀行/京橋支店/H&Iグローバルリサーチ株式会社)
Global Markets Direct社の概要及び新刊レポートはこちらでご確認いただけます。

★グローバルリサーチ資料[前立腺がん(Prostate Cancer):治療薬開発のグローバルパイプライン動向(2014年下半期版)]についてメールでお問い合わせはこちら
本調査レポートでは、世界における前立腺がん(Prostate Cancer)の治療薬開発パイプライン動向について調査・分析し、企業別開発中の治療薬、大学/研究機関で研究中の治療薬、各臨床試験段階における製品リスト及び比較分析、薬剤候補のプロファイル、治療薬の評価、開発中止又は開発休止中の製品リスト等をお届けしています。また、前立腺がん(Prostate Cancer)治療薬開発に取り組んでいる企業情報、業界の主要ニュースも提供しています。

・イントロダクション

・前立腺がん(Prostate Cancer)の概要

・前立腺がん(Prostate Cancer)治療薬の開発:パイプライン製品の概要、比較分析

・企業で開発中の治療薬

・大学/研究機関で研究中の治療薬

・パイプライン製品の概略

・企業別、開発中の製品

・大学/研究機関別、研究中の製品

・前立腺がん(Prostate Cancer)治療薬開発に取り組んでいる企業:企業別製品パイプライン

・前立腺がん(Prostate Cancer)治療薬の評価

・薬剤のプロファイル:説明、作用機序、研究開発(R&D)の進展状況

・パイプライン製品の最新動向

・開発休止中の製品/プロジェクト

・開発が中止された製品

・製品開発のマイルストーン
*** レポート概要(サマリー)***

Prostate Cancer – Pipeline Review, H2 2014

Summary

Global Markets Direct’s, ‘Prostate Cancer – Pipeline Review, H2 2014’, provides an overview of the Prostate Cancer’s therapeutic pipeline.

This report provides comprehensive information on the therapeutic development for Prostate Cancer, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Prostate Cancer and special features on late-stage and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- The report provides a snapshot of the global therapeutic landscape of Prostate Cancer
- The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in the therapeutics development for Prostate Cancer and enlists all their major and minor projects
- The report summarizes all the dormant and discontinued pipeline projects
- A review of the Prostate Cancer products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- A detailed assessment of monotherapy and combination therapy pipeline projects
- Coverage of the Prostate Cancer pipeline on the basis of target, MoA, route of administration and molecule type
- Latest news and deals relating related to pipeline products

Reasons to buy

- Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Develop strategic initiatives by understanding the focus areas of leading companies
- Identify and understand important and diverse types of therapeutics under development for Prostate Cancer
- Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
- Devise corrective measures for pipeline projects by understanding Prostate Cancer pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

*** レポート目次(コンテンツ)***

Table of Contents
Table of Contents 2
Introduction 11
Prostate Cancer Overview 12
Therapeutics Development 13
Prostate Cancer – Therapeutics under Development by Companies 15
Prostate Cancer – Therapeutics under Investigation by Universities/Institutes 36
Prostate Cancer – Pipeline Products Glance 41
Prostate Cancer – Products under Development by Companies 45
Prostate Cancer – Products under Investigation by Universities/Institutes 71
Prostate Cancer – Companies Involved in Therapeutics Development 77
Prostate Cancer – Therapeutics Assessment 313
Prostate Cancer – Recent Pipeline Updates 1039
Prostate Cancer – Dormant Projects 1283
Prostate Cancer – Discontinued Products 1312
Appendix 1314

List of Tables

Number of Products under Development for Prostate Cancer, H2 2014 64
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2014 65
Number of Products under Development by Companies, H2 2014 67
Number of Products under Development by Companies, H2 2014 (Contd..1) 68
Number of Products under Development by Companies, H2 2014 (Contd..2) 69
Number of Products under Development by Companies, H2 2014 (Contd..3) 70
Number of Products under Development by Companies, H2 2014 (Contd..4) 71
Number of Products under Development by Companies, H2 2014 (Contd..5) 72
Number of Products under Development by Companies, H2 2014 (Contd..6) 73
Number of Products under Development by Companies, H2 2014 (Contd..7) 74
Number of Products under Development by Companies, H2 2014 (Contd..8) 75
Number of Products under Development by Companies, H2 2014 (Contd..9) 76
Number of Products under Development by Companies, H2 2014 (Contd..10) 77
Number of Products under Development by Companies, H2 2014 (Contd..11) 78
Number of Products under Development by Companies, H2 2014 (Contd..12) 79
Number of Products under Development by Companies, H2 2014 (Contd..13) 80
Number of Products under Development by Companies, H2 2014 (Contd..14) 81
Number of Products under Development by Companies, H2 2014 (Contd..15) 82
Number of Products under Development by Companies, H2 2014 (Contd..16) 83
Number of Products under Development by Companies, H2 2014 (Contd..17) 84
Number of Products under Development by Companies, H2 2014 (Contd..18) 85
Number of Products under Development by Companies, H2 2014 (Contd..19) 86
Number of Products under Investigation by Universities/Institutes, H2 2014 88
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 89
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 90
Number of Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 91
Comparative Analysis by Late Stage Development, H2 2014 92
Comparative Analysis by Clinical Stage Development, H2 2014 93
Comparative Analysis by Early Stage Development, H2 2014 94
Comparative Analysis by Unknown Stage Development, H2 2014 95
Products under Development by Companies, H2 2014 96
Products under Development by Companies, H2 2014 (Contd..1) 97
Products under Development by Companies, H2 2014 (Contd..2) 98
Products under Development by Companies, H2 2014 (Contd..3) 99
Products under Development by Companies, H2 2014 (Contd..4) 100
Products under Development by Companies, H2 2014 (Contd..5) 101
Products under Development by Companies, H2 2014 (Contd..6) 102
Products under Development by Companies, H2 2014 (Contd..7) 103
Products under Development by Companies, H2 2014 (Contd..8) 104
Products under Development by Companies, H2 2014 (Contd..9) 105
Products under Development by Companies, H2 2014 (Contd..10) 106
Products under Development by Companies, H2 2014 (Contd..11) 107
Products under Development by Companies, H2 2014 (Contd..12) 108
Products under Development by Companies, H2 2014 (Contd..13) 109
Products under Development by Companies, H2 2014 (Contd..14) 110
Products under Development by Companies, H2 2014 (Contd..15) 111
Products under Development by Companies, H2 2014 (Contd..16) 112
Products under Development by Companies, H2 2014 (Contd..17) 113
Products under Development by Companies, H2 2014 (Contd..18) 114
Products under Development by Companies, H2 2014 (Contd..19) 115
Products under Development by Companies, H2 2014 (Contd..20) 116
Products under Development by Companies, H2 2014 (Contd..21) 117
Products under Development by Companies, H2 2014 (Contd..22) 118
Products under Development by Companies, H2 2014 (Contd..23) 119
Products under Development by Companies, H2 2014 (Contd..24) 120
Products under Development by Companies, H2 2014 (Contd..25) 121
Products under Investigation by Universities/Institutes, H2 2014 122
Products under Investigation by Universities/Institutes, H2 2014 (Contd..1) 123
Products under Investigation by Universities/Institutes, H2 2014 (Contd..2) 124
Products under Investigation by Universities/Institutes, H2 2014 (Contd..3) 125
Products under Investigation by Universities/Institutes, H2 2014 (Contd..4) 126
Products under Investigation by Universities/Institutes, H2 2014 (Contd..5) 127
Prostate Cancer - Pipeline by Baxter International Inc., H2 2014 128
Prostate Cancer - Pipeline by Johnson & Johnson, H2 2014 129
Prostate Cancer - Pipeline by Boehringer Ingelheim GmbH, H2 2014 130
Prostate Cancer - Pipeline by F. Hoffmann-La Roche Ltd., H2 2014 131
Prostate Cancer - Pipeline by Kyowa Hakko Kirin Co., Ltd., H2 2014 132
Prostate Cancer - Pipeline by Amgen Inc., H2 2014 133
Prostate Cancer - Pipeline by Sanofi, H2 2014 134
Prostate Cancer - Pipeline by AstraZeneca PLC, H2 2014 135
Prostate Cancer - Pipeline by Eli Lilly and Company, H2 2014 136
Prostate Cancer - Pipeline by Viralytics Ltd., H2 2014 137
Prostate Cancer - Pipeline by GlaxoSmithKline plc, H2 2014 138
Prostate Cancer - Pipeline by Bioniche Life Sciences, Inc., H2 2014 139
Prostate Cancer - Pipeline by Genentech, Inc., H2 2014 140
Prostate Cancer - Pipeline by Bavarian Nordic A/S, H2 2014 141
Prostate Cancer - Pipeline by Isis Pharmaceuticals, Inc., H2 2014 142
Prostate Cancer - Pipeline by Daiichi Sankyo Company, Limited, H2 2014 143
Prostate Cancer - Pipeline by Merck & Co., Inc., H2 2014 144
Prostate Cancer - Pipeline by Emergent BioSolutions Inc., H2 2014 145
Prostate Cancer - Pipeline by Oxford BioMedica plc, H2 2014 146
Prostate Cancer - Pipeline by Takeda Pharmaceutical Company Limited, H2 2014 147
Prostate Cancer - Pipeline by Amorfix Life Sciences Ltd., H2 2014 148
Prostate Cancer - Pipeline by Ipsen S.A., H2 2014 149
Prostate Cancer - Pipeline by MediGene AG, H2 2014 150
Prostate Cancer - Pipeline by Bio-Path Holdings, Inc., H2 2014 151
Prostate Cancer - Pipeline by Millennium Pharmaceuticals, Inc., H2 2014 152
Prostate Cancer - Pipeline by Novartis AG, H2 2014 153
Prostate Cancer - Pipeline by Samyang Holdings Corporation, H2 2014 154
Prostate Cancer - Pipeline by Aphios Corporation, H2 2014 155
Prostate Cancer - Pipeline by Astellas Pharma Inc., H2 2014 156
Prostate Cancer - Pipeline by GTx, Inc., H2 2014 157
Prostate Cancer - Pipeline by Ono Pharmaceutical Co., Ltd., H2 2014 158
Prostate Cancer - Pipeline by Orion Corp, H2 2014 159
Prostate Cancer - Pipeline by Pfizer Inc., H2 2014 160
Prostate Cancer - Pipeline by Astex Pharmaceuticals, Inc., H2 2014 161
Prostate Cancer - Pipeline by Teva Pharmaceutical Industries Limited, H2 2014 162
Prostate Cancer - Pipeline by Genmab A/S, H2 2014 163
Prostate Cancer - Pipeline by Progenics Pharmaceuticals, Inc., H2 2014 164
Prostate Cancer - Pipeline by Exelixis, Inc., H2 2014 165
Prostate Cancer - Pipeline by Aduro BioTech, Inc., H2 2014 166
Prostate Cancer - Pipeline by A. Menarini Industrie Farmaceutiche Riunite Srl, H2 2014 167
Prostate Cancer - Pipeline by Ferring International Center S.A., H2 2014 168
Prostate Cancer - Pipeline by Celgene Corporation, H2 2014 169
Prostate Cancer - Pipeline by Onyx Pharmaceuticals, Inc., H2 2014 170
Prostate Cancer - Pipeline by Bayer AG, H2 2014 171
Prostate Cancer - Pipeline by AntiCancer, Inc., H2 2014 172
Prostate Cancer - Pipeline by Merck KGaA, H2 2014 173
Prostate Cancer - Pipeline by Advaxis, Inc., H2 2014 174
Prostate Cancer - Pipeline by 4SC AG, H2 2014 175
Prostate Cancer - Pipeline by Alchemia Limited, H2 2014 176
Prostate Cancer - Pipeline by Harbor Therapeutics, Inc., H2 2014 177
Prostate Cancer - Pipeline by Celldex Therapeutics, Inc., H2 2014 178
Prostate Cancer - Pipeline by Anavex Life Sciences Corp., H2 2014 179
Prostate Cancer - Pipeline by ValiRx Plc, H2 2014 180
Prostate Cancer - Pipeline by Active Biotech AB, H2 2014 181
Prostate Cancer - Pipeline by AEterna Zentaris Inc., H2 2014 182
Prostate Cancer - Pipeline by Immunomedics, Inc., H2 2014 183
Prostate Cancer - Pipeline by Antisense Therapeutics Limited, H2 2014 184
Prostate Cancer - Pipeline by Arrowhead Research Corporation, H2 2014 185
Prostate Cancer - Pipeline by Lorus Therapeutics Inc., H2 2014 186
Prostate Cancer - Pipeline by MEI Pharma, Inc., H2 2014 187
Prostate Cancer - Pipeline by Bionomics Limited, H2 2014 188
Prostate Cancer - Pipeline by Northwest Biotherapeutics, Inc., H2 2014 189
Prostate Cancer - Pipeline by Novogen Limited, H2 2014 190
Prostate Cancer - Pipeline by Nymox Pharmaceutical Corporation, H2 2014 191
Prostate Cancer - Pipeline by Oncolytics Biotech Inc., H2 2014 192
Prostate Cancer - Pipeline by Oncothyreon Inc., H2 2014 193
Prostate Cancer - Pipeline by Compugen Ltd., H2 2014 194
Prostate Cancer - Pipeline by OXiGENE, Inc., H2 2014 195
Prostate Cancer - Pipeline by Patrys Limited, H2 2014 196
Prostate Cancer - Pipeline by Medivation, Inc., H2 2014 197
Prostate Cancer - Pipeline by ArQule, Inc., H2 2014 198
Prostate Cancer - Pipeline by Regeneron Pharmaceuticals, Inc., H2 2014 199
Prostate Cancer - Pipeline by Oncogenex Pharmaceuticals, Inc., H2 2014 200
Prostate Cancer - Pipeline by ProMetic Life Sciences Inc., H2 2014 201
Prostate Cancer - Pipeline by Galectin Therapeutics, Inc., H2 2014 202
Prostate Cancer - Pipeline by AnGes MG, Inc., H2 2014 203
Prostate Cancer - Pipeline by Quest PharmaTech Inc., H2 2014 204
Prostate Cancer - Pipeline by Synta Pharmaceuticals Corp., H2 2014 205
Prostate Cancer - Pipeline by Natco Pharma Limited, H2 2014 206
Prostate Cancer - Pipeline by Sareum Holdings plc, H2 2014 207
Prostate Cancer - Pipeline by Oasmia Pharmaceutical AB, H2 2014 208
Prostate Cancer - Pipeline by DiaMedica Inc., H2 2014 209
Prostate Cancer - Pipeline by Dongkook Pharmaceutical Co., Ltd., H2 2014 210
Prostate Cancer - Pipeline by Galena Biopharma, Inc., H2 2014 211
Prostate Cancer - Pipeline by Hybrigenics S.A., H2 2014 212
Prostate Cancer - Pipeline by Rexahn Pharmaceuticals, Inc., H2 2014 213
Prostate Cancer - Pipeline by Merrion Pharmaceuticals Plc, H2 2014 214
Prostate Cancer - Pipeline by Nanobiotix, H2 2014 215
Prostate Cancer - Pipeline by Solasia Pharma K.K., H2 2014 216
Prostate Cancer - Pipeline by Fujifilm Corporation, H2 2014 217
Prostate Cancer - Pipeline by Antigen Express, Inc., H2 2014 218
Prostate Cancer - Pipeline by Affitech A/S, H2 2014 219
Prostate Cancer - Pipeline by Isarna Therapeutics GmbH, H2 2014 220
Prostate Cancer - Pipeline by Colby Pharmaceutical Company, H2 2014 221
Prostate Cancer - Pipeline by Mayne Pharma Group Limited, H2 2014 222
Prostate Cancer - Pipeline by Chipscreen Biosciences Ltd, H2 2014 223
Prostate Cancer - Pipeline by CIMAB S.A., H2 2014 224
Prostate Cancer - Pipeline by Supratek Pharma Inc., H2 2014 225
Prostate Cancer - Pipeline by Camurus AB, H2 2014 226
Prostate Cancer - Pipeline by Fusion Antibodies Ltd, H2 2014 227
Prostate Cancer - Pipeline by Actinium Pharmaceuticals, Inc., H2 2014 228
Prostate Cancer - Pipeline by CellCentric Ltd., H2 2014 229
Prostate Cancer - Pipeline by Med Discovery SA, H2 2014 230
Prostate Cancer - Pipeline by Pro-Cure Therapeutics Limited, H2 2014 231
Prostate Cancer - Pipeline by immatics biotechnologies GmbH, H2 2014 232
Prostate Cancer - Pipeline by LIDDS AB, H2 2014 233
Prostate Cancer - Pipeline by Vaxon Biotech, H2 2014 234
Prostate Cancer - Pipeline by Advantagene, Inc., H2 2014 235
Prostate Cancer - Pipeline by CureVac GmbH, H2 2014 236
Prostate Cancer - Pipeline by Medeia Therapeutics Ltd., H2 2014 237
Prostate Cancer - Pipeline by Aileron Therapeutics, Inc., H2 2014 238
Prostate Cancer - Pipeline by Alethia Biotherapeutics Inc., H2 2014 239
Prostate Cancer - Pipeline by GenSpera, Inc., H2 2014 240
Prostate Cancer - Pipeline by Ascenta Therapeutics, Inc., H2 2014 241
Prostate Cancer - Pipeline by Tokai Pharmaceuticals, Inc., H2 2014 242
Prostate Cancer - Pipeline by Coronado Biosciences, Inc., H2 2014 243
Prostate Cancer - Pipeline by MacroGenics, Inc., H2 2014 244
Prostate Cancer - Pipeline by Provenance Biopharmaceuticals Corp., H2 2014 245
Prostate Cancer - Pipeline by Antyra, Inc., H2 2014 246
Prostate Cancer - Pipeline by Ambrx, Inc., H2 2014 247
Prostate Cancer - Pipeline by Arno Therapeutics, Inc., H2 2014 248
Prostate Cancer - Pipeline by Orphagen Pharmaceuticals, Inc., H2 2014 249
Prostate Cancer - Pipeline by Pantarhei Bioscience BV, H2 2014 250
Prostate Cancer - Pipeline by Azaya Therapeutics Incorporated, H2 2014 251
Prostate Cancer - Pipeline by Semafore Pharmaceuticals, Inc., H2 2014 252
Prostate Cancer - Pipeline by GP Pharm, S.A., H2 2014 253
Prostate Cancer - Pipeline by IC-MedTech, Inc., H2 2014 254
Prostate Cancer - Pipeline by Innate Therapeutics Limited, H2 2014 255
Prostate Cancer - Pipeline by ProNAi Therapeutics, Inc., H2 2014 256
Prostate Cancer - Pipeline by Angion Biomedica Corp., H2 2014 257
Prostate Cancer - Pipeline by Axelar AB, H2 2014 258
Prostate Cancer - Pipeline by Endocyte, Inc., H2 2014 259
Prostate Cancer - Pipeline by Omnitura Therapeutics Inc., H2 2014 260
Prostate Cancer - Pipeline by AndroScience Corporation, H2 2014 261
Prostate Cancer - Pipeline by Pharminox Limited, H2 2014 262
Prostate Cancer - Pipeline by Immutep S.A., H2 2014 263
Prostate Cancer - Pipeline by Esperance Pharmaceuticals, Inc., H2 2014 264
Prostate Cancer - Pipeline by Mirna Therapeutics, Inc., H2 2014 265
Prostate Cancer - Pipeline by Omeros Corporation, H2 2014 266
Prostate Cancer - Pipeline by TransTech Pharma, Inc., H2 2014 267
Prostate Cancer - Pipeline by Immunovaccine, Inc., H2 2014 268

List of Figures
Number of Products under Development for Prostate Cancer, H2 2014 64
Number of Products under Development for Prostate Cancer - Comparative Analysis, H2 2014 65
Number of Products under Development by Companies, H2 2014 66
Number of Products under Investigation by Universities/Institutes, H2 2014 87
Comparative Analysis by Late Stage Development, H2 2014 92
Comparative Analysis by Clinical Stage Development, H2 2014 93
Comparative Analysis by Early Stage Products, H2 2014 94
Assessment by Monotherapy Products, H2 2014 364
Assessment by Combination Products, H2 2014 365
Number of Products by Top 10 Target, H2 2014 366
Number of Products by Stage and Top 10 Target, H2 2014 367
Number of Products by Top 10 Mechanism of Action, H2 2014 376
Number of Products by Stage and Top 10 Mechanism of Action, H2 2014 377
Number of Products by Top 10 Route of Administration, H2 2014 387
Number of Products by Stage and Top 10 Route of Administration, H2 2014 388
Number of Products by Top 10 Molecule Type, H2 2014 390
Number of Products by Stage and Top 10 Molecule Type, H2 2014 391

*** 掲載企業 ***

Baxter International Inc.
Johnson & Johnson
Boehringer Ingelheim GmbH
F. Hoffmann-La Roche Ltd.
Kyowa Hakko Kirin Co., Ltd.
Amgen Inc.
Sanofi
AstraZeneca PLC
Eli Lilly and Company
Viralytics Ltd.
GlaxoSmithKline plc
Bioniche Life Sciences, Inc.
Genentech, Inc.
Bavarian Nordic A/S
Isis Pharmaceuticals, Inc.
Daiichi Sankyo Company, Limited
Merck & Co., Inc.
Emergent BioSolutions Inc.
Oxford BioMedica plc
Takeda Pharmaceutical Company Limited
Amorfix Life Sciences Ltd.
Ipsen S.A.
MediGene AG
Bio-Path Holdings, Inc.
Millennium Pharmaceuticals, Inc.
Novartis AG
Samyang Holdings Corporation
Aphios Corporation
Astellas Pharma Inc.
GTx, Inc.
Ono Pharmaceutical Co., Ltd.
Orion Corp
Pfizer Inc.
Astex Pharmaceuticals, Inc.
Teva Pharmaceutical Industries Limited
Genmab A/S
Progenics Pharmaceuticals, Inc.
Exelixis, Inc.
Aduro BioTech, Inc.
A. Menarini Industrie Farmaceutiche Riunite Srl
Ferring International Center S.A.
Celgene Corporation
Onyx Pharmaceuticals, Inc.
Bayer AG
AntiCancer, Inc.
Merck KGaA
Advaxis, Inc.
4SC AG
Alchemia Limited
Harbor Therapeutics, Inc.
Celldex Therapeutics, Inc.
Anavex Life Sciences Corp.
ValiRx Plc
Active Biotech AB
AEterna Zentaris Inc.
Immunomedics, Inc.
Antisense Therapeutics Limited
Arrowhead Research Corporation
Lorus Therapeutics Inc.
MEI Pharma, Inc.
Bionomics Limited
Northwest Biotherapeutics, Inc.
Novogen Limited
Nymox Pharmaceutical Corporation
Oncolytics Biotech Inc.
Oncothyreon Inc.
Compugen Ltd.
OXiGENE, Inc.
Patrys Limited
Medivation, Inc.
ArQule, Inc.
Regeneron Pharmaceuticals, Inc.
Oncogenex Pharmaceuticals, Inc.
ProMetic Life Sciences Inc.
Galectin Therapeutics, Inc.
AnGes MG, Inc.
Quest PharmaTech Inc.
Synta Pharmaceuticals Corp.
Natco Pharma Limited
Sareum Holdings plc
Oasmia Pharmaceutical AB
DiaMedica Inc.
Dongkook Pharmaceutical Co., Ltd.
Galena Biopharma, Inc.
Hybrigenics S.A.
Rexahn Pharmaceuticals, Inc.
Merrion Pharmaceuticals Plc
Nanobiotix
Solasia Pharma K.K.
Fujifilm Corporation
Antigen Express, Inc.
Affitech A/S
Isarna Therapeutics GmbH
Colby Pharmaceutical Company
Mayne Pharma Group Limited
Chipscreen Biosciences Ltd
CIMAB S.A.
Supratek Pharma Inc.
Camurus AB
Fusion Antibodies Ltd
Actinium Pharmaceuticals, Inc.
CellCentric Ltd.
Med Discovery SA
Pro-Cure Therapeutics Limited
immatics biotechnologies GmbH
LIDDS AB
Vaxon Biotech
Advantagene, Inc.
CureVac GmbH
Medeia Therapeutics Ltd.
Aileron Therapeutics, Inc.
Alethia Biotherapeutics Inc.
GenSpera, Inc.
Ascenta Therapeutics, Inc.
Tokai Pharmaceuticals, Inc.
Coronado Biosciences, Inc.
MacroGenics, Inc.
Provenance Biopharmaceuticals Corp.
Antyra, Inc.
Ambrx, Inc.
Arno Therapeutics, Inc.
Orphagen Pharmaceuticals, Inc.
Pantarhei Bioscience BV
Azaya Therapeutics Incorporated
Semafore Pharmaceuticals, Inc.
GP Pharm, S.A.
IC-MedTech, Inc.
Innate Therapeutics Limited
ProNAi Therapeutics, Inc.
Angion Biomedica Corp.
Axelar AB
Endocyte, Inc.
Omnitura Therapeutics Inc.
AndroScience Corporation
Pharminox Limited
Immutep S.A.
Esperance Pharmaceuticals, Inc.
Mirna Therapeutics, Inc.
Omeros Corporation
TransTech Pharma, Inc.
Immunovaccine, Inc.
Peptron, Inc.
Enceladus Pharmaceuticals BV
BIND Therapeutics, Inc.
NewLink Genetics Corporation
Seek
Cellceutix Corporation
IGF Oncology, LLC.
TVAX Biomedical, Inc.
Quintessence Biosciences, Inc.
Bellicum Pharmaceuticals, Inc.
AB Science
Aprea AB
Kinex Pharmaceuticals, LLC
Biokine Therapeutics Ltd.
Adamis Pharmaceuticals Corporation
CureTech Ltd.
Cylene Pharmaceuticals, Inc.
Genelux Corporation
WntResearch AB
Viventia Biotechnologies Inc.
IRX Therapeutics, Inc.
Vicus Therapeutics, LLC
Oncovir, Inc.
TRACON Pharmaceuticals, Inc.
EndoCeutics, Inc.
Dompe Farmaceutici S.p.A.
Advanced Cancer Therapeutics
Viamet Pharmaceuticals, Inc.
3-V Biosciences, Inc.
Soricimed Biopharma Inc.
Almac Discovery Ltd.
VaxOnco Inc
BHR Pharma, LLC
KAEL-GemVax Co., Ltd.
Beta Pharma, Inc.
iCeutica, Inc.
Incuron, LLC
Ausio Pharmaceuticals, LLC
Errant Gene Therapeutics, LLC
Mebiopharm Co., Ltd.
Polaris Group
Vaccibody AS
DEKK-TEC, Inc.
Serometrix, LLC
CytoVac A/S
Miami VA Healthcare System
Acino Pharma AG
Bio-Cancer Treatment International Limited
Karyopharm Therapeutics, Inc.
Tesaro, Inc.
APIM Therapeutics AS
EntreChem, S.L.
Cold Genesys, Inc.
Zensun (Shanghai) Sci & Tech Co., Ltd.
Polyplus-transfection SA
Kancera AB
Vaxeal Holding SA
Arrien Pharmaceuticals, LLC
Qu Biologics Inc.
CZ BioMed Corp
Evgen Limited
Activartis Biotech GmbH
Panacela Labs, Inc.
Io Therapeutics, Inc.
Avipep Pty Ltd
ATLAB Pharma SAS
Agonox
Tactic Pharma, LLC
Kadmon Corporation, LLC
RAPID Pharmaceuticals AG
Akshaya Bio Inc.
ADC Therapeutics Sarl
Foresee Pharmaceuticals, LLC
Antoxis Limited
Tolero Pharmaceuticals, Inc.
iTeos Therapeutics SA
DexTech Medical AB
Armour Therapeutics Inc.
AbbVie Inc.
OncoNOx ApS
Curadis GmbH
Medvio Eurasia
PSites Pharma GmbH
Pharmedartis GmbH
DormaTarg, Inc.
Oncology Research International Limited
Biscayne Pharmaceuticals, Inc.
Sotio a.s.
Galileo Research s.r.l.
Vasgen Limited
Balonco GMBH
OncoMax
SillaJen Co. Ltd.
Bionature E.A. Ltd.
TREAT U, S.A.

*** レポートのキーワード ***

前立腺がん(Prostate Cancer)治療薬、医薬品、研究開発、製薬企業、パイプライン、治験

*** 免責事項 ***
https://www.globalresearch.co.jp/disclaimer/


※おすすめ調査資料
※当サイト上のレポートデータは弊社H&Iグローバルリサーチ運営のMarketReport.jpサイトと連動しています。
※当市場調査資料(GMDHC5311IDB )"前立腺がん(Prostate Cancer):治療薬開発のグローバルパイプライン動向(2014年下半期版)" (英文:Prostate Cancer - Pipeline Review, H2 2014)はGlobal Markets Direct社が調査・発行しており、H&Iグローバルリサーチが販売します。


◆H&Iグローバルリサーチのお客様(例)◆


※当サイトに掲載していない調査資料も弊社を通してご購入可能ですので、お気軽にご連絡ください。ウェブサイトでは紹介しきれない資料も数多くございます。
※H&Iグローバルリサーチ(登録第5864124号)及びH&I(登録第5783645号)はH&Iグローバルリサーチ株式会社の商標です。